DAVID V. GOEDDEL - 18 May 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role: Director, 10%+ Owner
Signature: /s/ Valerie Pierce, Attorney-in-fact
Issuer symbol: NGM
Transactions as of: 18 May 2022
Transactions value $: $0
Form type: 4
Filing time: 20 May 2022, 18:22:03 UTC
Previous filing: 19 May 2022
Next filing: 23 May 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGM	Stock Option (Right to Buy)	Award	$0	+24.2K		$0.00	24.2K	18 May 2022	Common Stock	24.2K	$13.35	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date.

Content

The stock option shall vest in four (4) approximately equal quarterly installments, such that the option shall be fully vested on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day prior to the Issuer's next annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the Amended and Restated 2018 Equity Incentive Plan) on each applicable vesting date.